Healthy Clinical Trial
Official title:
The Effect of Experimental Neck Pain in Healthy Participants - The Transition From Acute to Ongoing Pain
This study investigates if/how an experimentally applied muscle pain/soreness, lasting for some days may affect brain activity, balance, movement patterns, muscle function and pain sensitivity in a healthy population
| Status | Recruiting |
| Enrollment | 40 |
| Est. completion date | May 1, 2019 |
| Est. primary completion date | May 1, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 50 Years |
| Eligibility |
Inclusion Criteria: - Healthy men and women aged 18-50 years - Only for sub-projects 1 and 2: Right-handed - Able to speak, read and understand Danish and English Exclusion Criteria: - Pain from the neck or shoulder area during the past 6 months - Experience of delayed onset muscle soreness (DOMS) during the week leading up to the test session - Former surgery in neck or shoulder - Current or previous chronic or recurrent pain condition - Pregnancy - Drug addiction defined as the use of cannabis, opioids or other drugs - Previous neurologic, musculoskeletal or mental illnesses - Regular use of analgesics - Abnormally disrupted sleep in the last 24 hours preceding the experiment - Lack of ability to cooperate - Unable to pass the TASS safety screening questionnaire for TMS |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Dept. Of Health Science and Technology, SMI, Aalborg University | Aalborg |
| Lead Sponsor | Collaborator |
|---|---|
| Aalborg University |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in pressure pain threshold (PPT) measured with a handheld pressure algometer | PPT will be assessed over head, neck, arm and leg sites. | Day 0, 2,4 and 15 | |
| Primary | Change in motor evoked potentials | Trans cranial magnetic stimulation (TMS) is used to asses motor evoked potentials of neck muscles | Day 0, 4 and 15 | |
| Primary | Change in Body movement | 3D recordings of body movements | Day 0, 4 and 15 | |
| Secondary | Change in muscle activity (EMG) | EMG of axioscapular muscles & trunk during arm movements | Day 0, 4 and 15 | |
| Secondary | Change in standing balance | Standing balance is measured on a force platform | Day 0, 4 and 15 | |
| Secondary | Change in perceived pain: McGill Pain Questionnaire | Pain will be scored using a scale from 0-10 with 0 being no pain and 10 being worst imaginable pain, by drawing on body charts and choosing words from the McGill Pain Questionnaire. | Day 0, 2,4 and 15 | |
| Secondary | Disability | Neck disability Index will be scored. Body movements will be scored on a modified 6-point Likert scale (0 = not difficult at all; 1 = minimally difficult; 2 = somewhat difficult; 3 = fairly difficult; 4 = very difficult; 5 = unable to perform) | Day 0, 2,4 and 15 | |
| Secondary | Pain Catastrophizing Scale (13 item questionnaire) | Pain Catastrophizing Scale (PCS) questionnaire. 13 items that can be answered with a Likert scale (0 = not at all, 1 = to a slight degree, 2= to a moderate degree, 3 = to a great degree, 4 = all the time). The PCS is scored by summing responses to all 13 items with scores ranging from 0 - 52. |
Day 2 | |
| Secondary | The Big Five Inventory (BFI) | BFI questionnaire investigates five general traits personality: extraversion, agreeableness, conscientiousness, neuroticism and openness. The BFI consists of 44 items that are answered on a 5 point Likert scale (1=Disagree strongly, 2=Disagree a little, 3=Neither agree or disagree, 4=Agree a little, 5=Agree strongly). This is not good/bad score in this questionnaire as it only assess personality traits. | Day 2 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |